GGrantIndex
← Leaderboards

Franca Cambi

University Of Pittsburgh At Pittsburgh

$3,748,123
Attributed
$4,653,583
Total exposure
8
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $765K · FY200625
$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$4,653,583 · 6
VA$0 · 2

By mechanism

R01$3,623,864 · 2
U10$566,804 · 1
R03$461,544 · 2
M01$1,371 · 1
I21$0 · 1
IS1$0 · 1

Top collaborators

Most similar at University Of Pittsburgh At Pittsburgh

Same institution · by research overlap

Others in their field

Top investigators on “Oligodendroglia

Research focus

OligodendrogliaCellsNeurodegenerative DisordersIn VivoNeuronsNerve DegenerationMyelinNeuroprotectionNeurogliaInnovationBrainFutureMotorNervous System DisorderTissuesPharmaceutical PreparationsUniversitiesCommunitiesProteinsAreaGeneticSiteNervous System StructureAffect

Grant awards (26)

Mechanisms of Oligodendrocyte Activity on Chronic Brain Implants and Recording Performance$609,737
R01 · FY2025 · NS
Mechanisms of Oligodendrocyte Activity on Chronic Brain Implants and Recording Performance$591,446
R01 · FY2024 · NS
Mechanisms of Oligodendrocyte Activity on Chronic Brain Implants and Recording Performance$609,737
R01 · FY2023 · NS
Cognitive decline in aging and AD: neuroprotection by hypermyelination in FusOLcKO$155,248
R03 · FY2023 · AG · contact PI
Cognitive decline in aging and AD: neuroprotection by hypermyelination in FusOLcKO$154,146
R03 · FY2022 · AG · contact PI
Novel ALS models: FUS conditional knockout in motor neurons and oligodendrocytes$0
I21 · FY2017 · VA · contact PI
Novel ALS models: FUS conditional knockout in motor neurons and oligodendrocytes$0
I21 · FY2016 · VA · contact PI
ShEEP request for Confocal Microscope$0
IS1 · FY2016 · VA · contact PI
NEUROPROTECTION EXPLORATORY TRIALS IN PD (NET-PD)$51,748
U10 · FY2013 · NS · contact PI
PLP alternative splicing and oligodendrocyte differentiation$314,059
R01 · FY2011 · NS · contact PI
Neuroprotection Exploratory Trials in PD (NET-PD)$106,914
U10 · FY2011 · NS · contact PI
PLP alternative splicing and oligodendrocyte differentiation$317,265
R01 · FY2010 · NS · contact PI
Neuroprotection Exploratory Trials in PD (NET-PD)$66,606
U10 · FY2010 · NS · contact PI
Neuroprotection Exploratory Trials in PD (NET-PD)$41,753
U10 · FY2010 · NS · contact PI
PLP alternative splicing and oligodendrocyte differentiation$320,469
R01 · FY2009 · NS · contact PI
PLP alternative splicing and oligodendrocyte differentiation$220,213
R01 · FY2009 · NS · contact PI
Neuroprotection Exploratory Trials in PD (NET-PD)$72,005
U10 · FY2009 · NS · contact PI
PLP alternative splicing and oligodendrocyte differentiation$320,469
R01 · FY2008 · NS · contact PI
Neuroprotection Exploratory Trials in PD (NET-PD)$137,468
U10 · FY2008 · NS · contact PI
PLP alternative splicing and oligodendrocyte differentiation$320,469
R01 · FY2007 · NS · contact PI
Neuroprotection Exploratory Trials in PD (NET-PD)$61,017
U10 · FY2007 · NS · contact PI
CREATINE IN PARTICIPANTS WITH TREATED PARKINSON'S DISEASE$1,371
M01 · FY2007 · RR · contact PI
Neuroprotection Exploratory Trials in PD (NET-PD)$29,293
U10 · FY2006 · NS · contact PI
PLP Splicing: In Vivo Analysis in A Mouse Model$73,649
R03 · FY2004 · HD
PLP Splicing: In Vivo Analysis in A Mouse Model$1
R03 · FY2004 · HD
PLP Splicing: In Vivo Analysis in A Mouse Model$78,500
R03 · FY2003 · HD